In the final video of this Rapid Reactions series, Beth Sandy, MSN, CRNP, FAPO, discusses data that continue to favor first-line amivantamab plus lazertinib over osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer after a median of 31 months of follow-up.
In this video, Beth Sandy, MSN, CRNP, FAPO, discusses data showing that zongertinib demonstrated manageable safety and promising efficacy in patients with HER2 aberration-positive solid tumors, including those with baseline brain metastases.
In this video, Beth Sandy, MSN, CRNP, FAPO, discusses ivonescimab, a bispecific antibody targeting PD-1 and VEGF that produced a tolerable safety profile and clinically significant improvement in efficacy compared with pembrolizumab.
Zongertinib, a HER2 TKI, demonstrated clinically meaningful activity and tolerability in patients with NSCLC with and without brain metastases harboring a HER2 mutation.
Sponsored by
Keep up to date with the latest news from us via social networks:
To sign up for our print publication or e-newsletter, please enter your contact information below.
